Fortress Biotech earnings release, August 13, 2026
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025
Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO® and UNLOXCYT™
Miami, FL – August 13, 2026 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2026.
Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “
The second quarter of 2026 reflected continued momentum across our portfolio and further progress in unlocking long-term shareholder value. Our subsidiary Urica Therapeutics, Inc.’s (“Urica”) equity position in Crystalys Therapeutics, Inc. (“Crystalys”) was strengthened by Crystalys' $130 million Series B financing, which will support the late-stage global development and commercialization preparation for dotinurad, a next-generation oral URAT1 inhibitor for gout, on which Urica is entitled to a 3% royalty on future net sales. Journey Medical also continues to scale Emrosi®, securing a third major GPO contract that expanded payer access to over 150 million commercial lives. Coming off the momentum of ZYCUBO®'s approval and the $205 million PRV sale in the first quarter, we enter the second half of 2026 with a favorable cash balance that positions us to continue executing on our pipeline and business development priorities.”
Dr. Rosenwald added, “We continued to see encouraging clinical progress this quarter on our partnered programs. AstraZeneca reported additional prespecified subgroup analyses for anselamimab (formerly CAEL-101) showing a 62% improvement in survival and a 71% reduction in cardiovascular hospitalizations among kappa predominant light chain isotype patients in the CARES program, and indicated that it plans to submit these findings to regulatory authorities. Crystalys also continues to advance dotinurad's two global Phase 3 trials while initiating a new Phase 2 study in difficult-to-treat gout, broadening the program's potential patient population. With a diversified portfolio spanning commercial, late-stage, and development-stage programs, including royalties, milestones and equity, and a strengthened balance sheet following the ZYCUBO® PRV monetization, we believe Fortress is well positioned to advance strategic initiatives and drive long-term value for our shareholders.”
Recent Corporate Highlights¹
:
Commercial Portfolio Updates¹
This press release references products being developed or commercialized by Fortress, by Fortress’ private or public subsidiaries (referred to herein as “subsidiaries” or “partner companies”) and by entities with whom one of the foregoing parties has a significant business relationship, such as an exclusive license or an ongoing product-related payment obligation (such entities referred to herein as “partners”). The words “we”, “us” and “our” may refer to Fortress individually, to one or more of our subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context.
Clinical Updates
Financial Results:
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.
Financial statements
Income Statement
Three Months Ended June 30, — ($ in thousands except for share and per share amounts)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Revenue | Product revenue, net | 17,839 | 15,009 | 33,760 | 28,148 |
| Revenue | Other revenue | 879 | 1,404 | 996 | 1,404 |
| Revenue | Net revenue | 18,718 | 16,413 | 34,756 | 29,552 |
| Operating expenses | Cost of goods - (excluding amortization of acquired intangible assets) | 6,143 | 4,939 | 12,361 | 9,729 |
| Operating expenses | Amortization of acquired intangible assets | 969 | 1,064 | 2,095 | 2,129 |
| Operating expenses | Research and development | 805 | 8,126 | 1,345 | 12,060 |
| Operating expenses | Selling, general and administrative | 20,807 | 38,757 | 36,699 | 64,424 |
| Operating expenses | Total operating expenses | 28,724 | 52,886 | 52,500 | 88,342 |
| Operating expenses | Loss from operations | -10,006 | -36,473 | -17,744 | -58,790 |
| Other income (expense) | Interest income | 1,581 | 622 | 2,151 | 1,112 |
| Other income (expense) | Interest expense and financing fee | -1,476 | -2,518 | -4,845 | -5,324 |
| Other income (expense) | Gain on sale of priority review voucher, net of expenses | 158,873 | |||
| Other income (expense) | Change in fair value of partner company derivative liability | -7,085 | |||
| Other income (expense) | Gain (loss) on common stock warrant liabilities | -350 | 1 | -397 | |
| Other income (expense) | Gain from deconsolidation of subsidiary | 82 | 27,127 | 82 | 27,127 |
| Other income (expense) | 10,741 | -62 | 11,783 | -73 | |
| Other income (expense) | Total other income | 10,928 | 24,819 | 160,960 | 22,445 |
| Other income (expense) | Income (loss) before income tax expense | 922 | -11,654 | 143,216 | -36,345 |
| Other income (expense) | Income tax expense | 320 | 5,452 | ||
| Other income (expense) | Net income (loss) | 602 | -11,654 | 137,764 | -36,345 |
| Other income (expense) | Attributable to non-controlling interests | -1,070 | 27,140 | -27,859 | 41,247 |
| Other income (expense) | Net income (loss) attributable to Fortress | -468 | 15,486 | 109,905 | 4,902 |
| Other income (expense) | Preferred A dividends cumulated, and Fortress' share of subsidiary deemed dividends | -2,008 | -2,131 | -4,016 | -4,261 |
| Other income (expense) | Net income (loss) attributable to common stockholders | -2,476 | 13,355 | 105,889 | 640 |
| Other income (expense) | Net income (loss) per common share attributable to common stockholders - basic | -0.08 | 0.5 | 3.34 | 0.02 |
| Other income (expense) | Net income (loss) per common share attributable to common stockholders - diluted | -0.08 | 0.45 | 2.86 | 0.02 |
| Other income (expense) | Weighted average common shares outstanding - basic | 31,791,173 | 26,879,380 | 31,666,585 | 26,679,106 |
| Other income (expense) | Weighted average common shares outstanding - diluted | 31,791,173 | 29,824,182 | 37,011,700 | 29,182,033 |
Balance Sheet
December 31, — ($ in thousands except for share and per share amounts)
| June 30, – 2026 | December 31, – 2025 | ||
|---|---|---|---|
| Current assets | Cash and cash equivalents | 196,576 | 79,381 |
| Current assets | Accounts receivable, net | 36,246 | 29,783 |
| Current assets | Inventory | 8,156 | 9,624 |
| Current assets | Other receivables - related party | 506 | 158 |
| Current assets | Prepaid expenses and other current assets | 4,022 | 4,895 |
| Current assets | Total current assets | 245,506 | 123,841 |
| Current assets | Property and equipment, net | 2,412 | 2,519 |
| Current assets | Operating lease right-of-use asset, net | 11,357 | 12,302 |
| Current assets | Restricted cash | 1,220 | 1,220 |
| Current assets | Equity investments, at fair value | 29,451 | 17,660 |
| Current assets | Intangible assets, net | 25,510 | 27,605 |
| Current assets | Other assets | 1,259 | 401 |
| Current assets | Total assets | 316,715 | 185,548 |
| Current liabilities | Accounts payable and accrued expenses | 49,325 | 47,125 |
| Current liabilities | Income taxes payable | 5,179 | 356 |
| Current liabilities | Common stock warrant liabilities | 1 | |
| Current liabilities | Operating lease liabilities, short-term | 2,246 | 2,127 |
| Current liabilities | Partner company notes payable, short-term | 5,000 | |
| Current liabilities | Other current liabilities | 268 | 135 |
| Current liabilities | Total current liabilities | 62,018 | 49,744 |
| Current liabilities | Notes payable, long-term, net | 34,602 | 52,417 |
| Current liabilities | Operating lease liabilities, long-term | 11,468 | 12,672 |
| Current liabilities | Partner company redeemable perpetual preferred liability | 7,085 | |
| Current liabilities | Other long-term liabilities | 2,541 | 1,447 |
| Current liabilities | Total liabilities | 110,629 | 123,365 |
| Stockholders’ equity | Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively, liquidation value of $25.00 per share | 3 | 3 |
| Stockholders’ equity | Common stock, $0.001 par value, 200,000,000 shares authorized, 33,311,012 and 31,364,094 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 33 | 31 |
| Stockholders’ equity | Additional paid-in-capital | 788,251 | 783,891 |
| Stockholders’ equity | Accumulated deficit | -624,147 | -734,052 |
| Stockholders’ equity | Total stockholders' equity attributed to the Company | 164,140 | 49,873 |
| Stockholders’ equity | Non-controlling interests | 41,946 | 12,310 |
| Stockholders’ equity | Total stockholders' equity | 206,086 | 62,183 |
| Stockholders’ equity | Total liabilities and stockholders' equity | 316,715 | 185,548 |
Full release
Forward-Looking Statements
Statements in this press release that are not descriptions of historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology are generally intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include risks relating to:... (truncated)ings; uncertainty related to the timing and amounts expected to be realized from future milestone, contingent value right, royalty or similar future revenue streams, if at all; our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; our ability to attract, integrate and retain key personnel; the early stage of product candidates under development; the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain regulatory approval for products under development; our ability to successfully commercialize products for which we receive regulatory approval or receive royalties or other distributions from third parties; our ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companies’ products and product candidates; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.
Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500 ir@fortressbiotech.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839 tplohoros@6degreespr.com
FORTRESS BIOTECH, INC. AND SUBSIDIARIES
Unaudited Condensed Consolidated Balance Sheets
($ in thousands except for share and per share amounts)
FORTRESS BIOTECH, INC. AND SUBSIDIARIES
Unaudited Condensed
Consolidated Statements of Operations
($ in thousands except for share and per share amounts)